Insider · CIK 0001226488
John T Henderson
director
Files at CYTK (CYTOKINETICS INC). First filing Dec 12, 2024, latest Dec 12, 2024.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $90k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CYTK: CYTOKINETICS INC
CYTKOct 9, 2026 · close 62.91
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Side | Company | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 4Weak | sell 410b5-1 | CYTK CYTOKINETICS INC | $90k | 1,780 | -4% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2025 | CYTK CYTOKINETICS INC | AGrant or award Common Stock | +434 | $48.93 | $21k | 48,987 | Jan 6, 2025 |
| Dec 11, 2024 | CYTK CYTOKINETICS INC | MOption exercise Common Stock10b5-1 | +1,780 | $7.37 | $13k | 40,241 | Dec 12, 2024 |
| Dec 11, 2024 | CYTK CYTOKINETICS INC | SOpen-market sale Common Stock10b5-1 | -1,780 | $50.42 | $90k | 38,461 | Dec 12, 2024 |
| Dec 11, 2024 | CYTK CYTOKINETICS INC | MOption exercise Common Stock10b5-1 | +10,092 | $7.37 | $74k | 48,553 | Dec 12, 2024 |
| Dec 11, 2024 | CYTK CYTOKINETICS INC | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -1,780 | $0.00 | $0 | 10,092 | Dec 12, 2024 |
| Dec 11, 2024 | CYTK CYTOKINETICS INC | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -10,092 | $0.00 | $0 | 0 | Dec 12, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.